Calluna Pharma is at the forefront of revolutionizing the treatment of inflammatory and fibrotic diseases. With a strong focus on harnessing the innate power of the immune system, Calluna Pharma aims to target the root causes of inflammation and fibrosis to provide effective therapy options. Their cutting-edge approach involves precision targeting of upstream amplifiers, resulting in the development of a robust pipeline of first-in-class therapeutic antibodies.

Spearheading their portfolio is CAL101, a monoclonal antibody designed to neutralize the bioactivity of S100A4. With a commitment to improving patient outcomes and challenging the status quo, Calluna Pharma offers hope to individuals suffering from serious and potentially life-threatening diseases such as idiopathic pulmonary fibrosis, chronic kidney disease, rheumatoid arthritis, and severe asthma. Join Calluna Pharma on their mission to reshape the treatment landscape and make a real difference in the lives of patients